Medibank Private（MPL）株式概要メディバンク・プライベート・リミテッドは、オーストラリアで民間医療保険と医療サービスを提供している。 詳細MPL ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長2/6過去の実績3/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より26.9%で取引されている 収益は年間9.87%増加すると予測されています リスク分析3.44%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない すべてのリスクチェックを見るMPL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,236 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,236 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$5.226.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture011b2016201920222025202620282031Revenue AU$11.5bEarnings AU$606.8mAdvancedSet Fair ValueView all narrativesMedibank Private Limited 競合他社nib holdingsSymbol: ASX:NHFMarket cap: AU$3.7bClearView WealthSymbol: ASX:CVWMarket cap: AU$405.2mSuncorp GroupSymbol: ASX:SUNMarket cap: AU$20.6bInsurance Australia GroupSymbol: ASX:IAGMarket cap: AU$20.0b価格と性能株価の高値、安値、推移の概要Medibank Private過去の株価現在の株価AU$5.2252週高値AU$5.3052週安値AU$4.07ベータ0.0531ヶ月の変化4.30%3ヶ月変化11.91%1年変化1.66%3年間の変化51.60%5年間の変化50.29%IPOからの変化142.56%最新ニュースお知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.最新情報をもっと見るRecent updatesお知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.Declared Dividend • Aug 30Final dividend of AU$0.10 announcedShareholders will receive a dividend of AU$0.10. Ex-date: 10th September 2025 Payment date: 9th October 2025 Dividend yield will be 3.5%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not adequately covered by earnings (99% earnings payout ratio) nor is it covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 10.0% to bring the payout ratio under control. EPS is expected to grow by 28% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.Reported Earnings • Aug 28Full year 2025 earnings released: EPS: AU$0.18 (vs AU$0.18 in FY 2024)Full year 2025 results: EPS: AU$0.18 (up from AU$0.18 in FY 2024). Revenue: AU$8.81b (up 9.7% from FY 2024). Net income: AU$500.8m (up 1.7% from FY 2024). Profit margin: 5.7% (down from 6.1% in FY 2024). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Insurance industry in Australia are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 11% per year.Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Jay Weatherill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne AustraliaDeclared Dividend • Aug 24Final dividend of AU$0.094 announcedShareholders will receive a dividend of AU$0.094. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 4.2%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not covered by earnings (dividend approximately 117x earnings). However, it is covered by cash flows (56% cash payout ratio). The dividend has increased by an average of 14% per year over the past 9 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 12,926% to bring the payout ratio under control. EPS is expected to grow by 127% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.お知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.New Risk • Aug 22New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.05% Last year net profit margin: 6.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (0.05% net profit margin).Board Change • Apr 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Director Jay Weatherill was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • Feb 24First half dividend increased to AU$0.072Dividend of AU$0.072 is 14% higher than last year. Ex-date: 29th February 2024 Payment date: 20th March 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is covered by earnings (62% earnings payout ratio) but not covered by cash flows (123% cash payout ratio). The dividend has increased by an average of 12% per year over the past 9 years and payments have been stable during that time. EPS is expected to decline by 5.2% over the next 3 years. However, it would need to fall by 31% to increase the payout ratio to a potentially unsustainable range.Reported Earnings • Feb 23First half 2024 earnings released: EPS: AU$0.13 (vs AU$0.061 in 1H 2023)First half 2024 results: EPS: AU$0.13 (up from AU$0.061 in 1H 2023). Revenue: AU$4.08b (up 12% from 1H 2023). Net income: AU$343.2m (up 103% from 1H 2023). Profit margin: 8.4% (up from 4.7% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, while revenues in the Insurance industry in Australia are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.New Risk • Feb 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.6% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (123% cash payout ratio).お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.Upcoming Dividend • Sep 06Upcoming dividend of AU$0.083 per share at 4.1% yieldEligible shareholders must have bought the stock before 13 September 2023. Payment date: 05 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 4.1%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (3.3%).お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.Reported Earnings • Aug 24Full year 2023 earnings released: EPS: AU$0.19 (vs AU$0.14 in FY 2022)Full year 2023 results: EPS: AU$0.19 (up from AU$0.14 in FY 2022). Revenue: AU$7.29b (up 2.6% from FY 2022). Net income: AU$511.1m (up 30% from FY 2022). Profit margin: 7.0% (up from 5.5% in FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 7% per year.お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.085 (vs AU$0.08 in 1H 2022)First half 2023 results: EPS: AU$0.085 (up from AU$0.08 in 1H 2022). Revenue: AU$3.69b (up 2.0% from 1H 2022). Net income: AU$233.3m (up 5.9% from 1H 2022). Profit margin: 6.3% (up from 6.1% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 5% per year.お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023Buying Opportunity • Dec 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be AU$3.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings is also forecast to grow by 7.3% per annum over the same time period.Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to AU$2.90, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Insurance industry in Australia. Total loss to shareholders of 3.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at AU$4.74 per share.Upcoming Dividend • Aug 31Upcoming dividend of AU$0.073 per shareEligible shareholders must have bought the stock before 07 September 2022. Payment date: 29 September 2022. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Australian dividend payers (6.6%). Higher than average of industry peers (2.8%).Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.14 (vs AU$0.16 in FY 2021)Full year 2022 results: EPS: AU$0.14 (down from AU$0.16 in FY 2021). Revenue: AU$7.10b (up 1.0% from FY 2021). Net income: AU$393.9m (down 11% from FY 2021). Profit margin: 5.5% (down from 6.3% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 5.2% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 1% per year and the company’s share price has also increased by 1% per year.Recent Insider Transactions • Mar 30Independent Non-Executive Director recently bought AU$151k worth of stockOn the 22nd of March, Gerard Dalbosco bought around 48k shares on-market at roughly AU$3.11 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Feb 27First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.08 (down from AU$0.082 in 1H 2021). Revenue: AU$3.61b (up 2.8% from 1H 2021). Net income: AU$220.2m (down 2.7% from 1H 2021). Profit margin: 6.1% (down from 6.4% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 4.6% compared to a 2.3% decline forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year.Upcoming Dividend • Sep 01Upcoming dividend of AU$0.069 per shareEligible shareholders must have bought the stock before 08 September 2021. Payment date: 30 September 2021. Trailing yield: 3.6%. Lower than top quartile of Australian dividend payers (5.2%). In line with average of industry peers (3.6%).Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$7.03b (up 3.7% from FY 2020). Net income: AU$441.2m (up 40% from FY 2020). Profit margin: 6.3% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Executive Departure • May 26CEO & Director Craig Drummond has left the companyOn the 17th of May, Craig Drummond, was replaced as CEO by David Koczkar after 4.9 years in the role. As of March 2021, Craig personally held 1.36m shares (AU$3.6m worth at the time). Craig is the only executive to leave the company over the last 12 months. Under Craig's leadership, the company delivered a total shareholder return of 29%.Is New 90 Day High Low • Feb 18New 90-day low: AU$2.83The company is down 4.0% from its price of AU$2.93 on 20 November 2020. The Australian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Insurance industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$3.15 per share.Is New 90 Day High Low • Dec 21New 90-day high: AU$3.06The company is up 18% from its price of AU$2.60 on 23 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$3.24 per share.Is New 90 Day High Low • Nov 14New 90-day high: AU$2.91The company is up 2.0% from its price of AU$2.87 on 14 August 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Insurance industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.78 per share.株主還元MPLAU InsuranceAU 市場7D1.0%-0.8%2.0%1Y1.7%-0.9%3.1%株主還元を見る業界別リターン: MPL過去 1 年間で-0.9 % の収益を上げたAustralian Insurance業界を上回りました。リターン対市場: MPLは、過去 1 年間で3.1 % のリターンを上げたAustralian市場を下回りました。価格変動Is MPL's price volatile compared to industry and market?MPL volatilityMPL Average Weekly Movement2.3%Insurance Industry Average Movement3.6%Market Average Movement9.6%10% most volatile stocks in AU Market16.8%10% least volatile stocks in AU Market3.9%安定した株価: MPL 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MPLの 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19763,604David Koczkarwww.medibank.com.auメディバンク・プライベート・リミテッドはオーストラリアで民間医療保険と医療サービスを提供している。同社は医療保険とメディバンク・ヘルスという2つのセグメントで事業を展開している。健康保険事業では、加入者に病院での治療を保障する病院保険や、歯科、眼鏡、理学療法などの医療サービスを保障する付帯保険などの民間医療保険商品を提供している。このセグメントでは、海外からの旅行者や留学生向けの医療保険商品も提供している。メディバンク・ヘルス部門は、政府および法人顧客向けに、健康管理、在宅介護サービス、各種遠隔医療サービスを提供し、旅行保険、生命保険、ペット保険商品を販売している。メディバンクとアームのブランドで医療保険商品を引き受けている。同社は1976年に設立され、オーストラリアのドックランズに本社を置いている。もっと見るMedibank Private Limited 基礎のまとめMedibank Private の収益と売上を時価総額と比較するとどうか。MPL 基礎統計学時価総額AU$14.40b収益（TTM）AU$463.40m売上高(TTM)AU$8.77b31.1xPER（株価収益率1.6xP/SレシオMPL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MPL 損益計算書（TTM）収益AU$8.77b売上原価AU$6.84b売上総利益AU$1.93bその他の費用AU$1.46b収益AU$463.40m直近の収益報告Dec 31, 2025次回決算日Aug 19, 2026一株当たり利益（EPS）0.17グロス・マージン21.97%純利益率5.28%有利子負債／自己資本比率1.5%MPL の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.4%現在の配当利回り110%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 12:23終値2026/08/04 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medibank Private Limited 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Andrew AdamsBarrenjoey Markets Pty LimitedJohn HesterBell PotterFreya KongBofA Global Research14 その他のアナリストを表示
お知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.
お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026
お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
お知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.
お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026
お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
Declared Dividend • Aug 30Final dividend of AU$0.10 announcedShareholders will receive a dividend of AU$0.10. Ex-date: 10th September 2025 Payment date: 9th October 2025 Dividend yield will be 3.5%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not adequately covered by earnings (99% earnings payout ratio) nor is it covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 10.0% to bring the payout ratio under control. EPS is expected to grow by 28% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
Reported Earnings • Aug 28Full year 2025 earnings released: EPS: AU$0.18 (vs AU$0.18 in FY 2024)Full year 2025 results: EPS: AU$0.18 (up from AU$0.18 in FY 2024). Revenue: AU$8.81b (up 9.7% from FY 2024). Net income: AU$500.8m (up 1.7% from FY 2024). Profit margin: 5.7% (down from 6.1% in FY 2024). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Insurance industry in Australia are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 11% per year.
Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Jay Weatherill was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.
お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australia
Declared Dividend • Aug 24Final dividend of AU$0.094 announcedShareholders will receive a dividend of AU$0.094. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 4.2%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is not covered by earnings (dividend approximately 117x earnings). However, it is covered by cash flows (56% cash payout ratio). The dividend has increased by an average of 14% per year over the past 9 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 12,926% to bring the payout ratio under control. EPS is expected to grow by 127% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
お知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.
New Risk • Aug 22New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.05% Last year net profit margin: 6.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (0.05% net profit margin).
Board Change • Apr 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Director Jay Weatherill was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • Feb 24First half dividend increased to AU$0.072Dividend of AU$0.072 is 14% higher than last year. Ex-date: 29th February 2024 Payment date: 20th March 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is covered by earnings (62% earnings payout ratio) but not covered by cash flows (123% cash payout ratio). The dividend has increased by an average of 12% per year over the past 9 years and payments have been stable during that time. EPS is expected to decline by 5.2% over the next 3 years. However, it would need to fall by 31% to increase the payout ratio to a potentially unsustainable range.
Reported Earnings • Feb 23First half 2024 earnings released: EPS: AU$0.13 (vs AU$0.061 in 1H 2023)First half 2024 results: EPS: AU$0.13 (up from AU$0.061 in 1H 2023). Revenue: AU$4.08b (up 12% from 1H 2023). Net income: AU$343.2m (up 103% from 1H 2023). Profit margin: 8.4% (up from 4.7% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, while revenues in the Insurance industry in Australia are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
New Risk • Feb 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.6% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (123% cash payout ratio).
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024
お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.
お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.
Upcoming Dividend • Sep 06Upcoming dividend of AU$0.083 per share at 4.1% yieldEligible shareholders must have bought the stock before 13 September 2023. Payment date: 05 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 4.1%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (3.3%).
お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.
Reported Earnings • Aug 24Full year 2023 earnings released: EPS: AU$0.19 (vs AU$0.14 in FY 2022)Full year 2023 results: EPS: AU$0.19 (up from AU$0.14 in FY 2022). Revenue: AU$7.29b (up 2.6% from FY 2022). Net income: AU$511.1m (up 30% from FY 2022). Profit margin: 7.0% (up from 5.5% in FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 7% per year.
お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.
お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
Reported Earnings • Feb 24First half 2023 earnings released: EPS: AU$0.085 (vs AU$0.08 in 1H 2022)First half 2023 results: EPS: AU$0.085 (up from AU$0.08 in 1H 2022). Revenue: AU$3.69b (up 2.0% from 1H 2022). Net income: AU$233.3m (up 5.9% from 1H 2022). Profit margin: 6.3% (up from 6.1% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 5% per year.
お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.
お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023
Buying Opportunity • Dec 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be AU$3.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 3.7% per annum. Earnings is also forecast to grow by 7.3% per annum over the same time period.
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to AU$2.90, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Insurance industry in Australia. Total loss to shareholders of 3.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at AU$4.74 per share.
Upcoming Dividend • Aug 31Upcoming dividend of AU$0.073 per shareEligible shareholders must have bought the stock before 07 September 2022. Payment date: 29 September 2022. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Australian dividend payers (6.6%). Higher than average of industry peers (2.8%).
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.14 (vs AU$0.16 in FY 2021)Full year 2022 results: EPS: AU$0.14 (down from AU$0.16 in FY 2021). Revenue: AU$7.10b (up 1.0% from FY 2021). Net income: AU$393.9m (down 11% from FY 2021). Profit margin: 5.5% (down from 6.3% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.6%, compared to a 5.2% growth forecast for the Insurance industry in Australia. Over the last 3 years on average, earnings per share has increased by 1% per year and the company’s share price has also increased by 1% per year.
Recent Insider Transactions • Mar 30Independent Non-Executive Director recently bought AU$151k worth of stockOn the 22nd of March, Gerard Dalbosco bought around 48k shares on-market at roughly AU$3.11 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Feb 27First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.08 (down from AU$0.082 in 1H 2021). Revenue: AU$3.61b (up 2.8% from 1H 2021). Net income: AU$220.2m (down 2.7% from 1H 2021). Profit margin: 6.1% (down from 6.4% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 4.6% compared to a 2.3% decline forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year.
Upcoming Dividend • Sep 01Upcoming dividend of AU$0.069 per shareEligible shareholders must have bought the stock before 08 September 2021. Payment date: 30 September 2021. Trailing yield: 3.6%. Lower than top quartile of Australian dividend payers (5.2%). In line with average of industry peers (3.6%).
Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$7.03b (up 3.7% from FY 2020). Net income: AU$441.2m (up 40% from FY 2020). Profit margin: 6.3% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Executive Departure • May 26CEO & Director Craig Drummond has left the companyOn the 17th of May, Craig Drummond, was replaced as CEO by David Koczkar after 4.9 years in the role. As of March 2021, Craig personally held 1.36m shares (AU$3.6m worth at the time). Craig is the only executive to leave the company over the last 12 months. Under Craig's leadership, the company delivered a total shareholder return of 29%.
Is New 90 Day High Low • Feb 18New 90-day low: AU$2.83The company is down 4.0% from its price of AU$2.93 on 20 November 2020. The Australian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Insurance industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$3.15 per share.
Is New 90 Day High Low • Dec 21New 90-day high: AU$3.06The company is up 18% from its price of AU$2.60 on 23 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Insurance industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$3.24 per share.
Is New 90 Day High Low • Nov 14New 90-day high: AU$2.91The company is up 2.0% from its price of AU$2.87 on 14 August 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Insurance industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$2.78 per share.
